Preliminary clinical evidence suggests a role for GLP-1RA and dipeptidyl peptidase 4 (DPP-4) inhibitors in the reduction of adverse clinical events in patients with T2D diagnosed with inflammatory bowel disease (IBD), such as lower rates of IBD-related hospitalizations, IBD-related major surgery, and reduced reliance on oral corticosteroids and TNF-α inhibitor drugs (9). This evidence concerns the gene DPP4 and inflammatory bowel disease.